Core Insights - NeurAxis, Inc. has announced medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, with Molina Healthcare, expanding its reach to approximately 5.1 million members across 13 states [1][3] - The IB-Stim device is FDA-cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21, addressing a significant gap as there are currently no FDA-approved drug therapies for children with such conditions [2][4] - The company has significantly increased its insurance coverage from 4 million to 51 million lives over the past year, highlighting the growing acceptance and demand for its technology [3] Company Overview - NeurAxis, Inc. focuses on neuromodulation therapies aimed at chronic and debilitating conditions in both children and adults, with a commitment to advancing science and evidence-based medicine [4] - The IB-Stim therapy is a proprietary technology that utilizes non-surgical methods to deliver electrical impulses to cranial nerve bundles, providing a novel treatment option for patients suffering from abdominal pain-related disorders [2][4] - Ongoing clinical trials are being conducted for PENFS in various pediatric and adult conditions, indicating the company's dedication to expanding its therapeutic applications [4]
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States